The Role of Dietary Diversity in Mitigating Pregnancy Distress: A Randomized Clinical Trial.

J Nutr Educ BehavJul 17, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Mozhgan Moshtagh, Mojtaba Daneshvar, Ghazaleh Banayee et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized clinical trial evaluated the impact of a dietary diversity intervention on pregnancy distress among pregnant women in Birjand city. The study involved 84 participants, with results showing significant reductions in pregnancy distress and improved dietary diversity scores in the intervention group (P < 0.001).

Key findings

  • The intervention group showed a significant reduction in pregnancy distress compared to the control group (P < 0.001).
  • Adjusted mean values of dietary diversity score were significantly higher in the intervention group (P < 0.001).
  • Changes in dietary diversity score were significantly correlated with changes in pregnancy distress (r = -0.41; P < 0.01).

Why it matters

Understanding the role of dietary diversity in reducing pregnancy distress can inform health initiatives aimed at improving maternal well-being, particularly in underdeveloped regions where nutritional education may be lacking.

Source

PubMed · PMID 42467028

Published in J Nutr Educ Behav. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.